March 6, 2013
/PRNewswire/ -- Hagens Berman Sobol Shapiro LLP, a law firm with experience prosecuting cases against healthcare providers and the pharmaceutical industry, today filed two lawsuits in Federal Court in
alleging that DaVita Healthcare Partners, Inc.'s (NYSE: DVA) ("DaVita") actions led to the deaths of two dialysis patients. The lawsuits further allege that the problems that caused those deaths have impacted thousands of dialysis patients across the country, and seek class action status.
The suits claim that DaVita – one of the nation's largest providers of dialysis services – failed to recognize that part of the treatment it used in dialysis was causing dangerously high levels of bicarbonates in the patients, which the suit claims caused the deaths of the two patients cited in the suits, and potentially many other unreported deaths and injuries, including cardiac arrest and stroke.
has also filed suits against Fresenius Medical Care North America (FMC) ("Fresenius"), the company who manufactured and distributed the two products. According to those lawsuits, an internal memo dated
Nov. 4, 2011
, reveals that Fresenius knew of the dangers associated with GranuFlo and NaturaLyte, two dialysis products, far in advance of informing the FDA. Moreover, the complaints allege that Fresenius made adjustments at its own clinics to reduce the impact on patients, showing it was aware of the problem.
The suits seek to represent patients who suffered cardiac arrest, stroke, respiratory issues or a litany of other health problems linked to the use of GranuFlo and NaturaLyte, both of which were recalled by the FDA on
March 29, 2012
Patients, former patients or their surviving families who believe they suffered from cardiac, stroke or other adverse events associated with the products are encouraged to contact
attorneys. You can reach an attorney by calling 888-381-2889 or by emailing
, managing partner of
, DaVita shares the blame, even though Fresenius manufactured and distributed the products. "Even before the FDA stepped in, our medical experts all conclude that DaVita should have recognized that its patients using the two products showed wild swings in their bicarbonate levels, a clear indication that they were at a much higher risk of cardiac arrest."
Berman also noted that DaVita failed to recognize trends in the number of complications and deaths after dialysis treatments. "Even had the company overlooked the trends relating to bicarbonate levels, we would expect that the high number of complications and deaths would have alerted them that something was amiss."